Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

UroGen Pharma Q3 Net Loss Widens, Revenue Rises; Shares Dip

11/15/2021 | 09:45am EST


ę MT Newswires 2021
All news about UROGEN PHARMA LTD.
01/18HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rati..
MT
01/07INSIDER SELL : Urogen Pharma
MT
01/05UroGen Pharma to Present at Upcoming Conferences
BU
2021First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients w..
AQ
2021Urogen Pharma Doses First Patient in Bladder Cancer Trial
MT
2021First Patient Dosed in UroGen Pharma's Home Instillation Study of UGN-102 in Patients w..
BU
2021UroGen Pharma Ltd. Doses First Patient in Home Instillation Study of UGN-102 in Patient..
CI
2021UroGen Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
2021UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
2021UroGen Pharma Q3 Net Loss Widens, Revenue Rises; Shares Dip
MT
More news
Analyst Recommendations on UROGEN PHARMA LTD.
More recommendations
Financials (USD)
Sales 2021 48,1 M - -
Net income 2021 -109 M - -
Net cash 2021 44,1 M - -
P/E ratio 2021 -1,51x
Yield 2021 -
Capitalization 163 M 163 M -
EV / Sales 2021 2,48x
EV / Sales 2022 0,43x
Nbr of Employees 198
Free-Float 91,1%
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | URGN | IL0011407140 | MarketScreener
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 7,28 $
Average target price 36,60 $
Spread / Average Target 403%
EPS Revisions
Managers and Directors
Elizabeth Barrett President, Chief Executive Officer & Director
Molly Henderson Chief Financial & Accounting Officer
Arie S. Belldegrun Chairman
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
UROGEN PHARMA LTD.-23.45%163
GILEAD SCIENCES, INC.-5.16%86 377
REGENERON PHARMACEUTICALS-1.05%65 339
VERTEX PHARMACEUTICALS10.66%61 849
WUXI APPTEC CO., LTD.-11.62%47 600
BIONTECH SE-37.08%39 180